MA29542B1 - Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role - Google Patents

Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Info

Publication number
MA29542B1
MA29542B1 MA30467A MA30467A MA29542B1 MA 29542 B1 MA29542 B1 MA 29542B1 MA 30467 A MA30467 A MA 30467A MA 30467 A MA30467 A MA 30467A MA 29542 B1 MA29542 B1 MA 29542B1
Authority
MA
Morocco
Prior art keywords
treatment
pathogenesis
role
hepatic diseases
iron plays
Prior art date
Application number
MA30467A
Other languages
English (en)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29542B1 publication Critical patent/MA29542B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE L'UTILISATION D'ACIDE 4-[3,5-BIS-(2-HYDROXYPHÉNYL)-[1,2,4]-TRIAZOL-1-YL]BENZOÏQUE (APPELÉ ICI 'COMPOSÉ I') DANS LA FABRICATION DE COMPOSITIONS PHARMACEUTIQUES UTILES DANS LE TRAITEMENT DE MALADIES HÉPATIQUES HUMAINES DANS LA PATHOGENÈSE DESQUELLES LE FER JOUE UN RÔLE, NOTAMMENT DES MALADIES VIRALES, TELLES QUE L'HÉPATITE C CHRONIQUE, FACULTATIVEMENT ASSOCIÉES À DES AGENTS ANTIVIRAUX, ET DANS LE TRAITEMENT DE MALADIES NON VIRALES, TELLES QUE LA STÉATOHÉPATITE NON ALCOOLIQUE ET LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE.
MA30467A 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role MA29542B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
MA29542B1 true MA29542B1 (fr) 2008-06-02

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30467A MA29542B1 (fr) 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Country Status (16)

Country Link
US (3) US20080199428A1 (fr)
EP (1) EP1893198A2 (fr)
JP (2) JP2008542380A (fr)
KR (2) KR101174966B1 (fr)
AU (1) AU2006252718B2 (fr)
BR (1) BRPI0610873A2 (fr)
CA (1) CA2608709A1 (fr)
CR (1) CR9454A (fr)
EA (1) EA014772B1 (fr)
IL (1) IL187000A0 (fr)
MA (1) MA29542B1 (fr)
MX (1) MX2007015085A (fr)
NO (1) NO20076595L (fr)
SM (1) SMAP200700061A (fr)
TN (1) TNSN07447A1 (fr)
WO (1) WO2006130532A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
EP1917037A2 (fr) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha et ribavirine permettant le traitement du virus hbv
BRPI0720793A2 (pt) 2006-11-29 2014-03-11 Novartis Ag SAIS E FORMAS CRISTALINAS DE ÁCIDO 4-[3,5-BIS(2-HIDRÓXI FENIL)-[1,2,4]tRIAZOL-1-IL]BENZOICO
EP1927591A1 (fr) * 2006-11-29 2008-06-04 Novartis AG Formes polymorphes de deferasirox (ICL670)
EA201391262A1 (ru) * 2011-03-02 2014-03-31 Джером Шентаг Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с
EP2583680A3 (fr) 2011-10-21 2013-06-12 Abbvie Inc. Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20140323412A1 (en) * 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SG11201607859SA (en) * 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB202005054D0 (en) * 2020-04-06 2020-05-20 Nemysis Ltd Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
JP2013082726A (ja) 2013-05-09
IL187000A0 (en) 2008-02-09
WO2006130532A2 (fr) 2006-12-07
EA200702384A1 (ru) 2008-06-30
EP1893198A2 (fr) 2008-03-05
WO2006130532A3 (fr) 2007-11-22
US20130109730A1 (en) 2013-05-02
MX2007015085A (es) 2008-01-17
US20080199428A1 (en) 2008-08-21
KR20100018057A (ko) 2010-02-16
NO20076595L (no) 2007-12-20
AU2006252718A1 (en) 2006-12-07
US20100098662A1 (en) 2010-04-22
EA014772B1 (ru) 2011-02-28
CA2608709A1 (fr) 2006-12-07
JP5869469B2 (ja) 2016-02-24
KR101174966B1 (ko) 2012-08-17
CR9454A (es) 2008-04-16
JP2008542380A (ja) 2008-11-27
BRPI0610873A2 (pt) 2010-08-03
TNSN07447A1 (en) 2009-03-17
SMAP200700061A (it) 2007-12-28
KR20080003933A (ko) 2008-01-08
AU2006252718B2 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MA29542B1 (fr) Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
EA200702198A1 (ru) Фармацевтические составы
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
CY1111755T1 (el) Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
MA32787B1 (fr) Peptides antiviraux therapeutiques
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
EP2005962A4 (fr) Agent therapeutique pour affection abdominale inflammatoire
NO20076405L (no) Anvendelse av 24-nor-UDCA
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
MA31130B1 (fr) Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications
EP1930002A4 (fr) Utilisation d'ester d'acide hydroxybenzoïque et d'analogues pour la fabrication d'un médicament pour la prévention et le traitement d'infection virale
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
PE20001496A1 (es) Formulacion de liberacion controlada para el tratamiento de epoc
NO20080890L (no) Sammensetninger for a redusere forekomsten av medikamentindusert arytmi
RU2007138263A (ru) Противовоспалительные соединения
BRPI0608287A2 (pt) agente endoparasiticida
MA31446B1 (fr) Inhibiteurs de raf pour le traitement du cancer de la thyroide